ACC

This channel contains news about the American College of Cardiology (ACC), including coverage of its annual meeting and links to recently released practice guidelines. The ACC is a leading resource for cardiology professionals, including all its subspecialties. 

Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018

March 20, 2018 — Febuxostat, a gout ...

Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018

March 20, 2018 — The anti-inflammatory...

Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018

March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart...

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a...

Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the...

Reducing Co-Payments Improves Patient and Physician Adherence to Guideline-Recommended Treatment Post-Heart Attack, late-breaking trial at ACC.18.

Image from presentation, "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study," Wang 

News | ACC | March 20, 2018

March 20, 2018 — When patients who had a heart attack were given vouchers to cover their co-payments for...

Edwards Lifesciences received European CE mark clearance for its self-expanding Centera transcatheter aortic valve replacement (TAVR) device for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.

Edwards Lifesciences received European CE mark clearance for its self-expanding Centera transcatheter aortic valve replacement (TAVR) device for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. This was the top structural heart story of the month of February 2018.

Feature | March 20, 2018 | Dave Fornell

Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC)...

Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

Image from presentation, "The PHARMCLO Study," Diego Ardissino, M.D., F.A.C.C. 

News | ACC | March 20, 2018

March 20, 2018 — Patients with acute coronary syndrome experienced a substantially lower rate of heart attack,...

Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care
News | ACC | March 20, 2018

March 20, 2018 — A pill combining low doses of three...

Managing Blood Pressure in Barbershops Yields Substantial Improvements

Image from presentation, "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops," Victor et al

News | ACC | March 20, 2018

March 20, 2018 — African-American men who received medical intervention aimed at controlling their...

Trial Bolsters Evidence in Favor of Closing Hole in Heart After Stroke
News | ACC | March 20, 2018

March 20, 2018 — Among people with a type of hole in the heart, known as patent foramen ovale (PFO), those who...

Videos | Congenital Heart | March 20, 2018

A discussion with Ami Bhatt, M.D., director of the adult...

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018

March 19, 2018 — The combined rate of death from any cause, heart attack or stroke within 18 months was not...

Self-Applied Chest Patch Catches Atrial Fibrillation More Quickly Than Usual Care
News | Wearables | March 19, 2018

March 19, 2018 — For people at heightened risk for...

Videos | Cath Lab | March 15, 2018

A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical...

Overlay Init